Gilead Sees Sales Growth Charge Forward In Q3
With its HIV portfolio benefitting from a post-pandemic recovery, the drug maker said demand for Biktarvy drove higher US and Europe sales, while oncology products saw growth of 79% year-over-year.
With its HIV portfolio benefitting from a post-pandemic recovery, the drug maker said demand for Biktarvy drove higher US and Europe sales, while oncology products saw growth of 79% year-over-year.